Online inquiry

IVTScrip™ mRNA-Anti-CSF1R, SNDX-6352(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15032MR)

This product GTTS-WQ15032MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CSF1R gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001288705.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1436
UniProt ID P07333
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CSF1R, SNDX-6352(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ15032MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ14754MR IVTScrip™ mRNA-Anti-TNFRSF8, SGN-35(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA SGN-35
GTTS-WQ51MR IVTScrip™ mRNA-Anti-TNFRSF17, 2857916(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA 2857916
GTTS-WQ185MR IVTScrip™ mRNA-Anti-VEGFA, 12-IgG1(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA 12-IgG1
GTTS-WQ9632MR IVTScrip™ mRNA-Anti-PDCD1, JNJ-63723283(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA JNJ-63723283
GTTS-WQ1885MR IVTScrip™ mRNA-Anti-PDCD1, AGEN2034(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AGEN2034
GTTS-WQ13469MR IVTScrip™ mRNA-Anti-ERBB2&TNFRSF9, PRS-343(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA PRS-343
GTTS-WQ11236MR IVTScrip™ mRNA-Anti-pcrV&psl, MEDI3902(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MEDI3902
GTTS-WQ14213MR IVTScrip™ mRNA-Anti-IL17A, RG4934(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA RG4934
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW